Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Market Cap | 215.06M |
| Revenue (ttm) | 3.94M |
| Net Income (ttm) | -111.27M |
| Shares Out | 78.13M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $1.66 |
| Previous Close | $1.72 |
| Change ($) | -0.06 |
| Change (%) | -3.49% |
| Day's Open | 1.68 |
| Day's Range | 1.63 - 1.80 |
| Day's Volume | 4,019,830 |
| 52-Week Range | 0.91 - 9.78 |
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...
Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) moved higher by 5.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 75.61% year over year to ($0...
As usual, no earnings reports are scheduled for release on Friday afternoon. And with just two weeks to go in the first calendar quarter of 2021, there are only two earnings reports that we think are wo...
Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medi...
• Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 hot small cap stocks on the move are Corbus Pharmaceuticals (NASDAQ: CRB...
Major disappointment last year due to lenabasum not meeting its endpoints in a phase 3 and phase 2 trial. Massive expectation meant that the company had to downsize significantly to keep operations going.
Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.
Corbus Pharma (CRBP) is seeing massive gains for CRBP stock on Tuesday despite a lack of recent news from the pharmaceuticals company. The post Corbus Pharma: 8 Things for CRBP Stock Investors to Know A...
Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q3 2020 Results - Earnings Call Transcript
Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) CEO Yuval Cohen On Q3 2020 Results - Quick Version Earnings Call Transcript
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -4.88% and -64.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 34.37% year over year to ($0.43), whi...
Norwood, MA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
On Tuesday, November 10, Corbus Pharmaceuticals (NASDAQ: CRBP) will release its latest earnings report. Benzinga's outlook for Corbus Pharmaceuticals is included in the following report.
Norwood, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Norwood, MA, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
Norwood, MA, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
Norwood, MA, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.
Norwood, MA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medic...
Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) shares were plummeting hard Tuesday following an adverse clinical data readout.
A late-stage clinical failure is weighing heavily on the biotech's stock today.
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.
Norwood, MA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative me...
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q2 2020 Results - Earnings Call Transcript
Norwood, MA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
Norwood, MA, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
Norwood, MA, July 29, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum's Phase 3 Data
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
What’s the choice between these U.K and U.S. biotech-cannabis companies?
Norwood, MA, July 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
Norwood, MA, June 29, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
Norwood, MA, June 22, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative med...
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for... [Read more...]
| Industry Biotechnology | Founded 2009 |
| CEO Yuval Cohen | Employees 76 |
| Stock Exchange NASDAQ | Ticker Symbol CRBP |
Financial Performance
In 2020, CRBP's revenue was $3.94 million, a decrease of -89.11% compared to the previous year's $36.14 million. Losses were -$111.27 million, 55.7% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for CRBP stock is "Hold." The 12-month stock price forecast is 2.23, which is an increase of 34.34% from the latest price.